SEC Filing Summary: AspenBio, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report (Form 8-K) was filed by AspenBio, Inc. on January 25, 2005, regarding events occurring on January 24, 2005. The filing discloses the entry into a material definitive employment agreement and the appointment of new principal officers and a director. Note: The request metadata referenced "Riot Platforms, Inc." and a 2005 date, but the source text explicitly identifies the registrant as AspenBio, Inc.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on corporate governance and executive compensation terms.
Material Changes
- Executive Appointment: Richard G. Donnelly was hired as President, Chief Executive Officer, and appointed as a Director.
- Leadership Transition: Jeffrey G. McGonegal, previously serving as interim CEO/President, will continue as Chief Financial Officer.
- Compensation Agreement: Mr. Donnelly's agreement includes a $150,000 annual base salary, performance-based bonuses, and stock options.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of risks and contingencies. The primary unusual item is the significant change in executive leadership and the specific terms of the new CEO's compensation package, including the grant of options to acquire 500,000 shares at an exercise price of $0.60 per share, vesting over three years.
Key Facts for Investor Verification
- Verify the exact terms of the employment agreement with Richard G. Donnelly (Exhibit 10.25).
- Confirm the vesting schedule and exercise price ($0.60) for the 500,000 stock options granted.
- Review the press release (Exhibit 99.1) for additional context on the strategic rationale for the leadership change.
- Check subsequent filings for any financial impact of the new executive compensation structure.